We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.93B
AUM Growth
-$733M
Cap. Flow
-$466M
Cap. Flow %
-9.46%
Top 10 Hldgs %
45.48%
Holding
165
New
19
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
OTLY
Oatly Group
OTLY
+$37.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$32.5M
3
TRML
Tourmaline Bio
TRML
+$31.6M
4
SAGE
Sage Therapeutics
SAGE
+$24.7M
5
VERV
Verve Therapeutics
VERV
+$20.8M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$98.3M
2
INTC icon
Intel
INTC
+$47M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$38.4M
4
AVGO icon
Broadcom
AVGO
+$34.8M
5
BEKE icon
KE Holdings
BEKE
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 74.23%
2 Consumer Discretionary 10.87%
3 Consumer Staples 0.74%
4 Industrials 0.47%
5 Materials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$536M 10.87%
14,818,300
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$327M 6.63%
71,178,364
– –
ONC
3
BeOne Medicines Ltd
ONC
$34.3B
$292M 5.92%
850,000
– –
C icon
4
CALL
Citigroup
C
$222B
$195M 3.95%
2,750,000
-250,000
-8% -$18.5M
SEER icon
5
Seer Inc
SEER
$118M
$183M 3.72%
5,588,366
– –
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$176M 3.57%
1,400,000
– –
ARGX icon
7
argenx
ARGX
$54.6B
$151M 3.06%
500,000
+50,000
+11% +$14.2M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$137M 2.79%
850,000
+125,000
+17% +$20.1M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$38.5B
$127M 2.58%
750,000
– –
GM icon
10
CALL
General Motors
GM
$81.7B
$118M 2.4%
2,000,000
-1,500,000
-43% -$88.2M
FATE icon
11
Fate Therapeutics
FATE
$270M
$117M 2.38%
1,350,000
+50,000
+4% +$4.03M
RUBY
12
DELISTED
Rubius Therapeutics, Inc
RUBY
$113M 2.3%
4,633,791
-250,000
-5% -$6.25M
MORF
13
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$104M 2.12%
1,819,186
– –
IGMS
14
DELISTED
IGM Biosciences
IGMS
$91.5M 1.86%
1,100,000
-25,000
-2% -$1.85M
GBIO
15
DELISTED
Generation Bio
GBIO
$75.7M 1.54%
281,419
– –
INTC icon
16
CALL
Intel
INTC
$435B
$73M 1.48%
1,300,000
– –
BMY icon
17
CALL
Bristol-Myers Squibb
BMY
$130B
$66.8M 1.36%
1,000,000
– –
NBP
18
NovaBridge Biosciences American Depositary Shares
NBP
$202M
$63M 1.28%
750,000
– –
SDGR icon
19
Schrodinger
SDGR
$1.14B
$60.3M 1.22%
797,445
– –
SRRK icon
20
Scholar Rock
SRRK
$5.92B
$57.8M 1.17%
2,000,000
– –
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$56.8M 1.15%
1,000,000
+350,000
+54% +$24.7M
F icon
22
CALL
Ford
F
$59.6B
$52M 1.06%
3,500,000
-3,500,000
-50% -$46.5M
CERE
23
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$51.2M 1.04%
2,000,000
-500,000
-20% -$7.16M
KLRS
24
Kalaris Therapeutics
KLRS
$79.5M
$45.9M 0.93%
101,016
– –
SWTX
25
DELISTED
SpringWorks Therapeutics
SWTX
$41.2M 0.84%
500,000
+100,000
+25% +$7.59M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2021 Portfolio in Review

As of Q2 2021, Artal Group held 165 positions worth $4.93B, down 13% from $5.66B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group withdrew a net $466M in Q2 2021, closing 21 positions and reducing 16 holdings. Its most notable exit was BioNTech, an estimated $98.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 69% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Artal Group opened a new position in Oatly Group worth $36.7M.

  • Artal Group's largest Q2 2021 buy was Oatly Group: 75,000 shares worth $36.7M.
  • Artal Group added most to Sage Therapeutics in Q2 2021, an estimated $24.7M increase.
  • Artal Group's biggest Q2 2021 reduction was TG Therapeutics, cutting an estimated $27.5M.
  • Artal Group fully exited BioNTech in Q2 2021, selling an estimated $98.3M.
  • Artal Group's ten largest holdings make up 45% of its $4.93B portfolio in Q2 2021.
  • Artal Group opened 19 new positions and closed 21 in Q2 2021.
  • Artal Group's portfolio value fell 13% quarter-over-quarter to $4.93B.

Based on Artal Group's 13F filing for Q2 2021, filed 13 Aug 2021.